Tuberculosis (TB) is curable, and yet the most lethal infectious disease in the world. Each year, nearly two million die of TB globally.The situation is exacerbated by the emergence of drug-resistant forms and their delayed diagnosis.
AarogyaAI exploits genomics and artificial intelligence to rapidly and comprehensively diagnose drug-resistant TB in a few hours, instead of weeks. This means that patients can be prescribed the right combination of drugs instantly. The company’s goal is to be the gold standard in TB diagnostics by 2023.
They have partnered with 11 leading diagnostic labs in India for validating their product. The world’s largest sequencing company Illumina Inc. (USA) has invested in them and Dr. Soumya Swaminathan, Chief Scientist, WHO is their advisor.
AarogyaAI are recipients of the BIRAC-TiE WinER Award 2020, TIDE 2.0 MeiTy (Govt. of India) grant and Semi-finalists of the
Aayushmaan Bharat PM JAY Startup Grand Challenge 2020. They were featured as one of the ‘Big Ideas – Express Check Up’ by
Outlook Business India.
Praapti Jayaswal did her PhD in tuberculosis research at the Translational Health Science and Technology Institute, India. Having spent over 12 years as a researcher at top institutes such as All India Institute of Medical Sciences and University of Toledo, USA, she developed expertise in molecular biology and genetics.
Avlokita Tiwari is a computational biologist with a Master’s in bioinformatics. After her stint at THSTI as a Tuberculosis researcher, she spent 5 years writing code for biological data at the University of Turku, Finland and at Okinawa Institute of Science and Technology, Japan. Her expertise lies in computational genomics.